Institute of Post-Graduate Medical Education and Research and Memorial Hospital, Brazil
Editorial
Vancomycin-resistant Staphylococcus aureus
Author(s): Dr. Sara James*
Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a global
risk to public health. One of the first-line treatments for MRSA infections is still
vancomycin. However, in recent years, isolates of S. aureus that are completely
resistant to vancomycin have emerged.
Clinical isolates of both Staphylococcus aureus and coagulase-negative staphylococci
have been found to be resistant to vancomycin. Given that vancomycin has long
been the treatment of choice for gram-positive organisms that are resistant to
antibiotics, the emergence of vancomycin resistance poses a serious threat to
public health. Even though major efforts are being made to learn more about
vancomycin resistance, a lot is still unknown at this time. The major epidemiologic,
microbiological, and clinical features of vancomycin resistance in S. aureus and
coagulase-negative.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 